• Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 154.96 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.53
▼ -0.13 (-3.55%)

This chart shows the closing price for OPTN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OptiNose Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPTN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPTN

Analyst Price Target is $9.00
▲ +154.96% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OptiNose in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 154.96% upside from the last price of $3.53.

This chart shows the closing price for OPTN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in OptiNose. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2021Cantor FitzgeraldReiterated RatingOverweightLow
11/17/2021BMO Capital MarketsLower TargetOutperform$16.00 ➝ $9.00Low
5/6/2021Royal Bank of CanadaLower Target$17.00 ➝ $10.00Medium
5/6/2021Cantor FitzgeraldLower TargetOverweight$18.00 ➝ $12.00High
7/16/2020Piper SandlerReiterated RatingOverweight ➝ Market Perform$19.00Medium
7/16/2020Royal Bank of CanadaReiterated RatingOutperform$17.00Medium
3/25/2020Royal Bank of CanadaReiterated RatingBuy$17.00Low
3/5/2020Cantor FitzgeraldLower TargetOverweight$27.00 ➝ $21.00High
2/7/2020Piper SandlerReiterated RatingBuy$24.00Low
12/18/2019CowenInitiated CoverageOutperform$25.00Low
8/13/2019BMO Capital MarketsLower TargetOutperform$26.00 ➝ $24.00High
8/12/2019Royal Bank of CanadaSet TargetBuy$20.00Low
5/9/2019Cantor FitzgeraldReiterated RatingBuy$27.00High
4/23/2019Piper Jaffray CompaniesSet TargetBuy$29.00Low
3/7/2019Royal Bank of CanadaLower TargetOutperform$25.00High
2/4/2019Cantor FitzgeraldReiterated RatingBuy$27.00High
11/26/2018Cantor FitzgeraldReiterated RatingOverweightLow
11/14/2018Cantor FitzgeraldLower TargetOverweight ➝ Overweight$30.00 ➝ $27.00High
8/15/2018Cantor FitzgeraldReiterated RatingOverweightLow
8/15/2018BMO Capital MarketsLower TargetOutperform ➝ Outperform$30.00 ➝ $28.00Medium
8/14/2018Piper Jaffray CompaniesSet TargetBuy$30.00High
8/14/2018Cantor FitzgeraldSet TargetBuy$30.00High
8/7/2018Cantor FitzgeraldInitiated CoverageOverweight$30.00High
7/18/2018Piper Jaffray CompaniesReiterated RatingBuy$34.00Medium
1/15/2018Piper Jaffray CompaniesSet TargetBuy$28.00Medium
11/7/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$33.00N/A
11/7/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$27.00N/A
11/7/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$27.00N/A
11/7/2017BMO Capital MarketsInitiated CoverageOutperform$29.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.50 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/7/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/5/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/3/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
OptiNose logo
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Read More

Today's Range

Now: $3.53
Low: $3.53
High: $3.74

50 Day Range

MA: $3.65
Low: $3.43
High: $4.02

52 Week Range

Now: $3.53
Low: $1.46
High: $4.30

Volume

102,293 shs

Average Volume

137,621 shs

Market Capitalization

$293.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OptiNose?

The following sell-side analysts have issued reports on OptiNose in the last twelve months: BMO Capital Markets, and Cantor Fitzgerald.
View the latest analyst ratings for OPTN.

What is the current price target for OptiNose?

1 Wall Street analysts have set twelve-month price targets for OptiNose in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 155.0%. BMO Capital Markets has the highest price target set, predicting OPTN will reach $9.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $9.00 for OptiNose in the next year.
View the latest price targets for OPTN.

What is the current consensus analyst rating for OptiNose?

OptiNose currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPTN will outperform the market and that investors should add to their positions of OptiNose.
View the latest ratings for OPTN.

What other companies compete with OptiNose?

How do I contact OptiNose's investor relations team?

OptiNose's physical mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company's listed phone number is (267) 364-3500 and its investor relations email address is [email protected] The official website for OptiNose is www.optinose.com. Learn More about contacing OptiNose investor relations.